-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Rebang Pharmaceutical-B (09637.HK) issued an announcement. The marketing application for AP301 capsules (a novel oral ferrophosphate binder) in the company's pipeline to treat hyperphosphatemia in patients with chronic kidney disease undergoing maintenance dialysis was officially accepted by China's State Drug Administration today. The marketing application for this new drug is mainly based on the results of the key phase III clinical trial RESPOND-1 completed by AP301 in China and other cumulative clinical data.

Zhitongcaijing·08/07/2026 09:33:08
Listen to the news
Zhitong Finance App News, Rebang Pharmaceutical-B (09637.HK) issued an announcement. The marketing application for AP301 capsules (a novel oral ferrophosphate binder) in the company's pipeline to treat hyperphosphatemia in patients with chronic kidney disease undergoing maintenance dialysis was officially accepted by China's State Drug Administration today. The marketing application for this new drug is mainly based on the results of the key phase III clinical trial RESPOND-1 completed by AP301 in China and other cumulative clinical data.